Palmitoylethanolamide shows limited efficacy in controlling cerebral cryptococcosis in vivo
Laboratory studyOther animalsWith amphotericin B (in one arm; palmitoylethanolamide also tested alone)
This study tested palmitoylethanolamide together with amphotericin B (in one arm; palmitoylethanolamide also tested alone). Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Laboratory study
- Subjects
- Mice infected intracerebrally with Cryptococcus neoformans; numbers not stated
- Dose used in the study
- Not stated in the abstract
- Duration
- Not stated in the abstract
- What was measured
- Survival and fungal burden after PEA, amphotericin B, the two combined, or amphotericin B with 5-fluorocytosine.
What the authors reported
PEA alone did not significantly prolong survival or reduce fungal burden. Combined with amphotericin B it had an additive effect on survival and fungal clearance, but this combination was less effective than standard amphotericin B plus 5-fluorocytosine. The authors conclude PEA alone is not effective as an antifungal in this model.
Limits of this study
A mouse infection model; it cannot show effect in people. A largely negative result for PEA alone. Doses and route are not in the abstract. The authors declare no conflict of interest.
Source
PubMed 37750714 · doi:10.1128/aac.00459-23
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.